FDA moves to strengthen public warnings on drug recalls

US Food and Drug Administration Commissioner Scott Gottlieb has issued a statement outlining steps the agency is taking to reform the process for public warnings on product recalls.

Dr Gottlieb said that, while most companies collaborate over voluntary recalls, there are situations where the FDA “may need to provide safety advice to marketplace to protect consumers.”

To this end, the FDA is issuing final guidance on the circumstances where a company should issue a public warning about a voluntary recall, with details on the general timeframe for such warnings, and the information that should be included.